Quantcast
Home > Quotes > ALLO

Allogene Therapeutics, Inc. Common Stock (ALLO) Quote & Summary Data

ALLO 
$26.22
*  
0.08
0.31%
Get ALLO Alerts
*Delayed - data as of Dec. 14, 2018  -  Find a broker to begin trading ALLO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
30
Today's High / Low
$ 27.905 / $ 25.51
Share Volume
547,838
50 Day Avg. Daily Volume
N/A
Previous Close
$ 26.14
52 Week High / Low
$ 35.55 / $ 21.67
Market Cap
3,185,275,634
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
547,838
50 Day Avg. Daily Volume:
N/A

Trading Range

The current last sale of $26.22 is 21.00% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 27.905 $ 35.55
 Low: $ 25.51 $ 21.67

Company Description (as filed with the SEC)

We are a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient's use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients. In collaboration with Servier, we are developing UCART19, a chimeric antigen receptor (CAR) T cell product candidate targeting CD19.  ... More ...  


Risk Grade

Where does ALLO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 25.67
Open Date:
Dec. 14, 2018
Close Price:
$ 26.22
Close Date:
Dec. 14, 2018

Consensus Recommendation

Analyst Info